Veranex announces dual appointments

Med tech industry service provider Veranex has announced the appointment of industry veteran Tom Daulton as chief executive officer (CEO).

Former CEO David Dockhorn is assuming the newly created role of chief operating officer (COO).

Daulton has over 30 years of healthcare leadership experience, joining from National Dentex Labs, where he served as chairman and CEO and built one of the largest dental lab networks in North America.

His earlier experience includes key roles at medical device and major healthcare services organisations with global scale, including Baxter, Allegiance Healthcare and Cardinal Health.

Daulton was also founder and CEO of Devicor Medical Products, which acquired Mammotome’s breast care business from J&J’s Ethicon Endo-Surgery.

Daulton said:

“I am thrilled to join this exceptional team and continue the progress David has already championed.

“As an end-to-end MedTech service provider, Veranex is clearly poised for an exciting future.”

As COO, Dockhorn will focus on operational excellence as Veranex continues its global expansion through both acquisition-driven and organic growth.

He will support Daulton in business integration and in developing the organisational structure necessary to support Veranex’s growing global footprint.

Dockhorn said:

“I am proud of the company we are building and the impact we are making every day with our customers.

“I am excited to strengthen our impact by focusing on building the operational teams that support organic growth as we continue to build out our capabilities and enhance our operations, while Tom focuses on leading the organisation and helping it expand.”

Veranex Board of Directors Chairman, Patrick Donnelly, said:

“The Veranex board is thrilled to welcome Tom to lead the company through this next stage of growth.

“Tom is a proven leader with deep experience in MedTech and in leading global companies.

“His experience, combined with David’s operational leadership expertise, enables Veranex to deepen our capability to help our clients deliver innovation that has a true impact on the lives of patients everywhere.”